Lemoine A, Lambaudie E, Bonnet F, Leblanc E, Alfonsi P
Service d'anesthésie, hôpital Tenon, médecine Sorbonne université, 75020 Paris, France.
Inserm, département de chirurgie oncologique, institut Paoli Calmettes, Aix-Marseille université, CNRS, 13000 Marseille, France.
Gynecol Obstet Fertil Senol. 2019 Feb;47(2):187-196. doi: 10.1016/j.gofs.2018.12.005. Epub 2019 Jan 24.
The following recommendations cover the perioperative management of ovarian, Fallopian tube and primary peritoneal cancers. Five questions related to pre-habilitation and enhanced recovery after surgery were evaluated. The conclusions and recommendations are based on an analysis of the level of evidence available in the literature. These recommendations are part of the overall recommendations for improving the management of ovarian, fallopian or primary peritoneal cancer, made with the support of INCa (Institut National du Cancer). The main preoperative measures are screening for nutritional deficiencies (Grade B) and for anaemia (GradeC) in patients with ovarian cancer. It is not possible to make recommendations on the correction of malnutrition and/or anemia or on the contribution of pre-operative immuno-nutrition due to the absence of data in ovarian cancer, tube cancer or primary peritoneum cancer. For the same reasons, no recommendation can be made on the value of preoperative digestive preparation in ovarian, fallopian tube or primary peritoneum cancer. During surgery, goal-directed fluid therapy for patients with advanced ovarian cancer is recommended (Grade B). A single dose infusion of tranexamic acid is recommended for patients with ovarian, fallopian tube or primary peritoneal cancer (GradeC). For postoperative analgesia, epidural analgesia is recommended for patients undergoing cyto-reduction surgery by laparotomy (Grade B). In the absence of epidural analgesia, patient controlled analgesia with morphine without continuous infusion (Grade B) is recommended. No recommendation can be given regarding intravenous administration of lidocaine and/or ketamine during surgery, or, regarding peri-operatively prescription of gabapentin or pregabalin. In the absence of studies on the impact of different non-opiate analgesic combinations for ovarian cancer surgery, no recommendations can be made. Early oral feeding is recommended, including in cases of digestive resection (Grade B). The implementation of enhanced recovery programs, including early mobilization, is recommended (GradeC).
以下建议涵盖卵巢癌、输卵管癌和原发性腹膜癌的围手术期管理。对与术前康复和术后加速康复相关的五个问题进行了评估。结论和建议基于对文献中现有证据水平的分析。这些建议是在法国国家癌症研究所(INCa)的支持下,为改善卵巢癌、输卵管癌或原发性腹膜癌管理而制定的总体建议的一部分。主要的术前措施是筛查卵巢癌患者的营养缺乏情况(B级)和贫血情况(C级)。由于卵巢癌、输卵管癌或原发性腹膜癌缺乏相关数据,无法就营养不良和/或贫血的纠正或术前免疫营养的作用提出建议。出于同样原因,对于卵巢癌、输卵管癌或原发性腹膜癌术前消化准备的价值也无法提出建议。手术期间,建议对晚期卵巢癌患者进行目标导向液体治疗(B级)。建议对卵巢癌、输卵管癌或原发性腹膜癌患者单次输注氨甲环酸(C级)。对于术后镇痛,建议对接受剖腹减瘤手术的患者采用硬膜外镇痛(B级)。若没有硬膜外镇痛,建议采用无持续输注的吗啡患者自控镇痛(B级)。对于手术期间静脉注射利多卡因和/或氯胺酮,或围手术期使用加巴喷丁或普瑞巴林,无法给出建议。由于缺乏关于不同非阿片类镇痛组合对卵巢癌手术影响的研究,无法提出建议。建议尽早开始经口进食,包括在进行消化器官切除的情况下(B级)。建议实施包括早期活动在内的加速康复计划(C级)。